Bioniq Raises $15M Series B Funding
Summary
Bioniq, a London, UK-based provider of personalized supplements based on blood biomarker data, raised $15M in Series B funding. Led by CEO Vadim Fedotov, Bioniq specializes in offering AI-driven personalized supplements based on blood test data. Shipping globally, the company has created formulas for over 100,000 users that incorporate components and dosages to each individual’s nutrient deficiencies, as identified through their blood results. Our AI-driven approach and extensive biochemical database allow us to create customized supplements that provide quantifiable results and cater to individuals’ specific needs. Beyond meeting consumer demand, we’re setting a new standard in the industry by making the process and results transparent to the users.”